Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.

Abstract: A vaccine preparation comprising an antigen for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, wherein the antigen is linked to a binder of a dermal migratory antigen-presenting cell (APC); and a pharmaceutical preparation comprising an active substance for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, for regional delivery to a target location. The invention further relates to the laser-assisted intradermal administration of antigens accompanied by repeated chemotherapy.

Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.

Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.

Abstract: The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.

Abstract: The present invention relates to an RNA vaccine comprising an RNA molecule encoding an allergen or derivative thereof and uses thereof.

Abstract: The present invention relates to a method for identifying a hypoallergenic derivative of a wild-type allergen comprising: determining the three-dimensional structure of a wild-type allergen; introducing at least one point mutation into said wild-type allergen, thereby obtaining a mutated allergen; identifying a hypoallergenic derivative of said wild-type allergen by detecting a destabilisation or change of the three-dimensional structure of the mutated allergen compared to the wild-type allergen by determining energy differences between the wild-type allergen and the mutant allergen expressed as a Z-score.

Abstract: Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen.